Revolutionizing 3D Medical Imaging

CT‑quality 3D navigation. From four X‑rays.

See All AI generates sliceable, high‑resolution 3D volumes from four standard fluoroscopic images, on the C‑arms already installed in roughly 150,000 operating rooms worldwide. No intraoperative CT. No CT radiation burden. No million‑dollar machine.

See All AI See3D reconstruction shown alongside conventional CT imaging
See3D™ volumetric reconstruction compared with conventional CT. Image: seeall.ai
$33M

Series funding closed, May 20251

3

Foundational U.S. patents with allowable subject matter1

150K

Fluoroscopy units worldwide our software can elevate to 3D1

30+

Team members with 500+ years of combined experience2

The Problem

3D surgical navigation today costs a room, a fortune, and a CT dose.

Image‑guided surgery improves accuracy, but the price of admission is an intraoperative CT platform. Most of the world's operating rooms will never have one.

$560K+

Capital cost

An O‑arm™ II runs about A$850,000 (≈US$560K); a mobile intraoperative CT like Airo® ranges up to A$1.2M, before the navigation platform is added.3

4.4×

Radiation exposure

In pediatric spine fusion, intraoperative CT navigation averaged 1.48 mSv effective dose versus 0.34 mSv with C‑arm fluoroscopy.4 A single spinal CT delivers over 3,100% more radiation than a standard fluoroscopy image.1

1,800 lbs

Footprint

Intraoperative CT means moving an 816 kg (1,800 lb) gantry plus a navigation tower in and out of sterile ORs.5 The C‑arm is already there.

A minority

Global access

Only well‑funded hospitals can justify the spend. Rural clinics, community hospitals, and most of the world operate without 3D guidance at all.2

Leveraging AI, Deep Learning, and Machine Vision

Software that turns the world's installed C‑arms into 3D navigation suites.

See All AI is pioneering a breakthrough in medical imaging, harnessing AI and deep learning to elevate what's possible in diagnostic and intraoperative 3D volumetric imaging.2

See3D™

Four shots. A full 3D volume.

From four intraoperative fluoroscopic X‑rays, the platform reconstructs a high‑resolution volume, sliceable in 1 mm cross‑sections across multiple planes, with fidelity comparable to CT. It eliminates the need for pre‑operative CTs, MRIs, or additional intraoperative imaging systems.1

Track All™

Sub‑millimeter tracking. No markers.

A proprietary visible‑light machine vision camera tracks surgical instruments with sub‑millimeter accuracy, without markers, emitters, or the direct line‑of‑sight that infrared navigation systems require.1

Green Vision™

Seeing with natural clarity.

The human eye is most sensitive to green light, the most vivid and detailed color we perceive. Our computer vision is designed to emulate that sensitivity to enhance 3D vision.2

Green Vision: computer vision emulating the human eye's sensitivity to green light
Why We Win

The same 3D guidance. Without the machine that costs more than the OR.

Incumbent 3D navigation bundles imaging hardware, tracking hardware, and software into a seven‑figure ecosystem. We replace the hardware with software.

See All AI platform vs. intraoperative CT navigation (O‑arm™ / Airo® class)
DimensionSee All AIIntraoperative CT navigation
Imaging source The standard C‑arm already in the OR; 3D reconstructed from a four‑shot fluoro workflow Dedicated cone‑beam or fan‑beam CT gantry brought into the OR
Patient radiation Standard fluoroscopy‑level exposure; a spinal CT delivers 3,100%+ more than a fluoro image [1] CT‑class dose; 1.48 vs 0.34 mSv measured against fluoro in spine fusion [4]
Capital cost Software‑first platform on existing equipment ≈US$560K (O‑arm™ II) to A$1.2M (Airo®), plus navigation platform [3]
Added OR footprint A visible‑light camera 816 kg (1,800 lb) gantry, optional 350 lb column, navigation tower [5]
Instrument tracking Track All™ visible‑light vision, sub‑millimeter, no markers or line‑of‑sight [1] Infrared cameras with reflective marker arrays requiring constant line‑of‑sight
Pre‑operative imaging Designed to eliminate pre‑op CT/MRI for navigation [1] Typically registered to pre‑operative CT or an intraoperative spin
Addressable install base ≈150,000 fluoroscopy units worldwide [1] Limited to hospitals that can fund a seven‑figure imaging suite
Global Access

Every C‑arm on Earth is a potential customer.

Imagine a world where patients everywhere can be treated with the highest‑quality technology, where physicians at leading institutions, in rural clinics, urban hospitals and remote communities are empowered with tools to See All.2

Software economics

An open, software‑based approach to imaging instead of expensive hardware or closed ecosystems, in the words of our CEO. Software scales; gantries don't.1

Beyond the incumbents' reach

Intraoperative CT sells to the top of the hospital pyramid. A software platform on existing C‑arms addresses the ≈150,000‑unit installed base the incumbents can't touch.1

Reduced complexity

3D image‑guided navigation that reduces complexity, radiation, operating room time, and cost.1

Global access: empowering patient care everywhere
Global access, empowering patient care. Image: seeall.ai
The Team

Built by the people who built the incumbents.

Our founder invented the O‑arm™ at Breakaway Imaging and led Mobius Imaging, developer of the Airo® system, the two platforms this technology now leapfrogs.1

Gene Gregerson

Gene Gregerson

Founder & Chief Innovation Officer

Founded Breakaway Imaging, where he invented the O‑arm™ intraoperative imaging system, and led Mobius Imaging, developer of Airo®.1

Eric Major

Eric Major

Chief Executive Officer

Veteran medtech executive; former President & CEO of spine company K2M.6

Dr. Todd Albert

Dr. Todd Albert

Chief Medical Officer

Surgeon‑in‑Chief Emeritus, Hospital for Special Surgery, New York City.1

Get In Touch

The next platform shift in surgical imaging is software.

$33M raised. Three foundational patents with allowable subject matter. A team that built this market once already. Based in Nashua, New Hampshire.

Regulatory status: See All AI's technologies are in the development phase and have not yet received FDA clearance. These technologies are not intended for clinical use until appropriate regulatory approvals are obtained.2 Comparative figures on this page are drawn from the published sources listed below; they describe third‑party systems and independent studies, not cleared claims about See All AI products.